Reference health
Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms
1 of 128 checkable references need attention · checked 2026-07-25
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
marked retracted — notice via Crossref, record curated by Retraction Watch10.1111/j.1460-9568.2009.06664.x
RETRACTED: Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity
The 127 checked references that resolve
resolves10.1016/j.smim.2016.04.006
Complement inhibition in biomaterial- and biosurface-induced thromboinflammation
resolves10.1111/imr.12471
Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross‐talk act as a linchpin in the events leading to thromboinflammation
resolves10.1097/MOT.0b013e3283425365
Platelets: versatile modifiers of innate and adaptive immune responses to transplants
resolves10.1007/s00296-018-4001-9
From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders
resolves10.1161/01.RES.47.3.301
A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis.
resolves10.1016/S0002-9440(10)64824-9
Inhibition of the Tissue Factor-Thrombin Pathway Limits Infarct Size after Myocardial Ischemia-Reperfusion Injury by Reducing Inflammation
resolves10.1161/ATVBAHA.107.141911
Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis
resolves10.1186/cc1854
resolves10.1182/blood-2009-12-259267
Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice
resolves10.1182/blood-2003-09-3051
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia
resolves10.1001/jama.290.2.238
Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
resolves10.1074/jbc.M116.754325
Polyphosphate and RNA Differentially Modulate the Contact Pathway of Blood Clotting
resolves10.1111/j.1538-7836.2011.04478.x
Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome
resolves10.1182/blood-2011-07-368811
Polyphosphate is a cofactor for the activation of factor XI by thrombin
resolves10.1084/jem.20052458
Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis
resolves10.1084/jem.190.1.91
Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage
resolves10.1182/blood.V96.7.2329
Modulation of hemostatic mechanisms in bacterial infectious diseases
resolves10.1016/j.pharmthera.2011.01.003
Structure, function and pathophysiology of protease activated receptors
resolves10.1074/jbc.M108555200
Genetic Evidence That Protease-activated Receptors Mediate Factor Xa Signaling in Endothelial Cells
resolves10.1016/j.molmed.2008.08.001
Factor Xa: at the crossroads between coagulation and signaling in physiology and disease
resolves10.1254/jphs.08126FP
Thrombin-Stimulated Proliferation of Cultured Human Synovial Fibroblasts Through Proteolytic Activation of Proteinase-Activated Receptor-1
resolves10.1161/ATVBAHA.109.185801
Thrombin Induces EGF Receptor Expression and Cell Proliferation via a PKC(δ)/c-Src-Dependent Pathway in Vascular Smooth Muscle Cells
resolves10.1182/blood-2009-01-200915
Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation
resolves10.1371/journal.pone.0043916
PR3 and Elastase Alter PAR1 Signaling and Trigger vWF Release via a Calcium-Independent Mechanism from Glomerular Endothelial Cells
resolves10.1016/j.thromres.2005.11.008
Detection of up-regulated genes in thrombin-stimulated human umbilical vein endothelial cells
resolves10.1016/j.abb.2015.09.012
Relationship between calcium mobilization and platelet α- and δ-granule secretion. A role for TRPC6 in thrombin-evoked δ-granule exocytosis
resolves10.1111/j.1538-7836.2006.01789.x
P2Y12 receptor‐mediated potentiation of thrombin‐induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation
resolves10.1182/blood-2003-08-2804
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions
resolves10.1038/ncomms8835
Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4
resolves10.1097/CCM.0b013e31819c06bc
Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)*
resolves10.1111/jth.13230
Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta‐analysis of randomized controlled trials
resolves10.1038/srep25984
Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials
resolves10.1007/s00134-017-4683-6
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
resolves10.1128/IAI.67.9.4463-4468.1999
Sulfated Polysaccharide-Directed Recruitment of Mammalian Host Proteins: a Novel Strategy in Microbial Pathogenesis
resolves10.1007/s00134-016-4225-7
Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis
resolves10.1056/NEJM200103083441001
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
resolves10.1182/blood-2004-01-0110
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity
resolves10.1038/nm760
Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation
resolves10.1182/blood-2007-02-075440
Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation
resolves10.1182/blood-2014-09-599910
Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar
resolves10.1016/j.blre.2014.10.006
Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent
resolves10.1038/jcbfm.2009.283
Deficiency of PAR4 Attenuates Cerebral Ischemia/Reperfusion Injury in Mice
resolves10.1124/jpet.109.162602
Parstatin(1-26): The Putative Signal Peptide of Protease-Activated Receptor 1 Confers Potent Protection from Myocardial Ischemia-Reperfusion Injury
resolves10.1111/jth.12841
Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta‐analysis
resolves10.1517/14728222.2016.1086750
Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases
resolves10.1111/j.1538-7836.2006.02267.x
Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial
resolves10.1097/CCM.0b013e31828e9b03
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*
resolves10.1097/00024382-199810000-00005
RANDOMIZED, BLINDED, PLACEBO-CONTROLLED TRIAL OF TISSUE FACTOR PATHWAY INHIBITOR IN PORCINE SEPTIC SHOCK
resolves10.1007/s001340100992
Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock
resolves10.1172/JCI116529
Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.
resolves10.1182/blood.V95.4.1124.002k20_1124_1129
Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
resolves10.1097/00003246-200111000-00007
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
resolves10.1016/j.bcmd.2005.12.014
The intrinsic pathway of coagulation is essential for thrombus stability in mice
resolves10.1160/TH10-05-0307
Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis
resolves10.1182/blood-2007-10-120139
Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
resolves10.1016/j.drudis.2014.06.024
Factor XII: a drug target for safe interference with thrombosis and inflammation
resolves10.1126/scitranslmed.3006804
A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk
resolves10.1161/STROKEAHA.112.660340
C1-Inhibitor Protects From Brain Ischemia-Reperfusion Injury by Combined Antiinflammatory and Antithrombotic Mechanisms
resolves10.1371/journal.pone.0146783
The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats
resolves10.1182/blood-2011-10-386185
Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis
resolves10.1111/jth.12797
Fasxiator, a novel factor XIa inhibitor from snake venom, and its site‐specific mutagenesis to improve potency and selectivity
resolves10.1056/NEJMoa1405760
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
resolves10.1182/blood-2014-05-577932
Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis
resolves10.1002/hep.28003
Imaging the dynamic platelet‐neutrophil response in sterile liver injury and repair in mice
resolves10.1016/j.thromres.2013.07.002
Use of antiplatelet agents in sepsis: A glimpse into the future
resolves10.1001/archinternmed.2009.42
Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery
resolves10.1161/CIRCULATIONAHA.116.024637
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction
resolves10.3109/09537104.2012.724482
Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock
resolves10.1212/WNL.0000000000001844
Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke
resolves10.1007/s11239-012-0833-4
Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness
resolves10.1080/10739680490266216
Glycoprotein IIB/IIIA‐Inhibition and Microcirculatory Alterations During Experimental Endotoxemia—An Intravital Microscopic Study in the Rat
resolves10.1182/blood.V89.11.4078
7E3 F(ab′)2 , a Monoclonal Antibody to the Platelet GPIIb/IIIa Receptor, Protects Against Microangiopathic Hemolytic Anemia and Microvascular Thrombotic Renal Failure in Baboons Treated With C4b Binding Protein and a Sublethal Infusion of Escherichia coli
resolves10.1097/00003246-200106000-00019
Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock
resolves10.1371/journal.pone.0041549
Platelets Induce Apoptosis during Sepsis in a Contact-Dependent Manner That Is Inhibited by GPIIb/IIIa Blockade
resolves10.1016/j.jacbts.2018.05.005
Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia
resolves10.1111/j.1538-7836.2005.01124.x
GPIIb–IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention
resolves10.1016/S0735-1097(00)01016-0
Platelet GPIIb/IIIa receptor blockade reduces infarct size in a canine model of ischemia-reperfusion
resolves10.1161/01.ATV.20.10.2226
c7E3Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen
resolves10.1038/sj.jcbfm.9600013
FK419, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, Ameliorates Brain Infarction Associated with Thrombotic Focal Cerebral Ischemia in Monkeys: Comparison with Tissue Plasminogen Activator
resolves10.1002/path.2916
Clopidogrel protects from cell apoptosis and oxidative damage in a mouse model of renal ischaemia–reperfusion injury
resolves10.1002/ajh.10451
Risk of bleeding complications with antiplatelet agents: Meta‐analysis of 338,191 patients enrolled in 50 randomized controlled trials
resolves10.1016/S0140-6736(09)61751-7
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data
resolves10.1371/journal.pone.0066960
The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
resolves10.1161/CIRCULATIONAHA.110.980623
Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans
resolves10.1161/STROKEAHA.115.011114
Efficacy and Safety of Platelet Glycoprotein Receptor Blockade in Aged and Comorbid Mice With Acute Experimental Stroke
resolves10.1182/blood-2017-06-788067
Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteria
resolves10.1172/JCI79070
Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets
resolves10.1182/blood-2004-01-0315
A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and platelets
resolves10.4049/jimmunol.1102674
Soluble Trem-like Transcript-1 Regulates Leukocyte Activation and Controls Microbial Sepsis
resolves10.1172/JCI36175
TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans
resolves10.1182/blood-2018-03-841593
Platelet-derived TLT-1 is a prognostic indicator in ALI/ARDS and prevents tissue damage in the lungs in a mouse model
resolves10.1016/j.blre.2006.06.001
Platelet-neutrophil-interactions: Linking hemostasis and inflammation
resolves10.1161/01.CIR.94.6.1239
Increased Neutrophil-Platelet Adhesion in Patients With Unstable Angina
resolves10.1097/FJC.0000000000000233
First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin
resolves10.1182/blood-2002-06-1887
The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome
resolves10.1097/01.CCM.0000138558.16257.3F
Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock*
resolves10.1097/00003246-199707000-00001
Anti-inflammatory therapies to treat sepsis and septic shock
resolves10.1182/blood-2011-10-387464
Emerging role of serpinE2/protease nexin-1 in hemostasis and vascular biology
resolves10.1074/jbc.M116.755660
Thrombin Cleavage of Inter-α-inhibitor Heavy Chain 1 Regulates Leukocyte Binding to an Inflammatory Hyaluronan Matrix
resolves10.1182/blood-2012-02-412080
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway
The 7 references without a DOI — listed, not checked
no DOI — not checkedRegulation of tissue factor expression
no DOI — not checkedBlood-borne tissue factor (including microparticles)
no DOI — not checkedRole of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation
no DOI — not checkedClinical evaluation of new therapeutic concepts in septic shock
no DOI — not checkedRecombinant human activated protein C for severe sepsis in neonates
no DOI — not checkedEffects of acetylsalicylic acid on the canine response to endotoxin
no DOI — not checkedProtective effects of aspirin in endotoxic shock
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-25 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1182/blood-2018-11-882993"><img src="https://citestamp.com/citestamped/10.1182/blood-2018-11-882993/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1182/blood-2018-11-882993)